和黃醫藥(00013.HK)將舉辦專家會議討論免疫性血小板減少症
格隆匯8月21日丨和黃醫藥(00013.HK)今日宣佈將舉辦醫師專家會議 ，邀請一位免疫性血小板減少症領域的教授及意見領袖討論免疫性血小板減少症的治療前景 。會議將於 2024 年 8 月 28 日(星期三)中國香港時間晚上 7 時，通過網絡直播舉行。
本次活動以中文(普通話)進行，並可通過 www.hutch-med.com/event 註冊收聽。有興趣收聽網絡線上直播的投資者請在會議開始前訪問網站，以便下載所需的軟件。會議的文字紀要(包括英文翻譯)將於活動後的 90天內提供。本次會議僅面向投資者。
ESLIM-01 研究是一項和黃醫藥的創新候選藥物索樂匹尼布 (sovleplenib)用於治療原發性免疫性血小板減少症的中國 III 期臨牀試驗 。該研究已達到所有終點，其結果已於 《柳葉刀·血液病學 (The Lancet Haematology)》發表，並於歐洲血液協會(EHA)年會上以口頭報吿的形式公佈。和黃醫藥已於 2024 年 1 月於中國提交索樂匹尼布的新藥上市申請。
據悉，免疫性血小板減少症是一種自身免疫疾病，表現為血小板受免疫性破壞以及血小板生成減少。免疫性血小板減少症的患者有着更高的過度出血和瘀傷風險。免疫性血小板減少症還與疲乏（成年免疫性血小板減少症患者中報吿率多達 39%）和生活質量受損有關。成人原發免疫性血小板減少症的發病率估計為每年每 10 萬成人中有 3.3 名，患病率為每 10 萬成人中有 9.5 名。 根據上述患病率數據，中國估計約有 11 萬名原發免疫性血小板減少症患者，此外美國、德國、法國、意大利、西班牙、英國和日本約有 5.6 萬名患者。在除中國以外的主要醫藥市場中，據估計有多達 14.5 萬名慢性免疫性血小板減少症患者。
索樂匹尼布是一種探索性的新型、選擇性的口服小分子 Syk 抑制劑。Syk 作為 B 細胞受體和 Fc 受體信號傳導通路中的一個關鍵蛋白，是多種亞型的 B 細胞淋巴瘤及自身免疫疾病的成熟治療靶點。索樂匹尼布目前正在臨牀研究中，其安全性和療效尚未得到任何監管機構的評估。和黃醫藥目前擁有索樂匹尼布在全球範圍內的所有權利。
除了免疫性血小板減少症(NCT05029635)外，索樂匹尼布用於治療温抗體性自身免疫性溶血性貧血(NCT05535933)和惰性非霍奇金淋巴瘤(NCT03779113)的研究亦在進行中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
